COVID-19：Dr. Reddy’s､クウェートでAVIGAN治験終了：感染初期に（動画）：
COVID-19: Dr. Reddy ’s AVIGAN trial in Kuwait: in early infection：
COVID-19：Reddy博士在科威特完成AVIGAN试验：早期感染的治疗作用
インド後発薬大手・ドクター・レディーズ・ラボラトリーズ
AVIGANの治験：
1月28日までに、「クウェートで実施しているCOVID-19治療薬候補AVIGANの治験」を終了する。
クウェートでの治験結果：
富士フイルムホールディングスが、アビガンを提供。
中等症の患者353人が参加。
アビガンを投与した患者は偽薬を投与した患者に比べて、
症状が改善するまでの日数が1日短かった。
しかし、有効性が確認できるような有意差はなかった。
一方、症状の軽い感染初期の患者に、治療効果が認められた。
日本経済新聞
https://www.nikkei.com/article/DGXZQODZ283WA0Y1A120C2000000
Dr. Reddy’s and GRA announce Avigan Pivotal Studies Update Study for hospitalized moderate to severe cases in Kuwait terminated,
while study for out-patient mild to moderate cases continues in North America
Hyderabad, India, January 27, 2021:
Dr. Reddy’s Laboratories Ltd. and
Global Response Aid FZCO (GRA)
today announced the termination of the Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID-19 patients in a hospital setting.
The hospitalized patient study, conducted in Kuwait, on moderate to severe patients
was one of the studies in the overall clinical program for Avigan, spanning the spectrum of asymptomatic to severe cases of COVID-19 in both out-patient and in-patient setting.
The Phase-III study, being conducted in an out- patient setting on patients with mild to moderate symptoms in North America by Dr. Reddy’s, in partnership with Appili Therapeutics and Global Response Aid, shall continue.
The data from the Kuwait CVD-04-CD-001 study involving moderate to severe COVID-19 hospitalized patients
did not show a statistically significant difference for the primary endpoint (i.e., time to sustained hypoxia resolution) for Avigan vs. placebo (7 days vs. 8 days; p= >0.05).
The full data analysis on 353 subjects would be available by the end of February 2021.
Within this group, there was subgroup analysis carried out on 181 patients in the low risk category.
The subgroup analysis of the low-risk (low NEWS Score at admission) study cohort (n=181) demonstrated a 3 day earlier discharge in the Avigan group compared to the placebo group (8 days vs. 11 days; p=0.0063) for time to hospital discharge secondary endpoint.
The subgroup analysis data during the initial interim analysis points towards the hypothesis with clinically significant insights from this study
that an antiviral drug such as Avigan may be effective as part of early treatment initiation in COVID-19 patients and not effective in the late-stage hospital treatment for moderate and severe COVID-19 patients.
Dr. Reddy’s, in partnership with Appili Therapeutics and Global Response Aid,
shall continue the Phase III pivotal study [PRESECO] being conducted in North America in an out-patient setting.
The PRESECO study
aims to determine the efficacy of Avigan as an early treatment for COVID-19 patients with mildto moderate symptoms, with the goal of alleviating symptoms and preventing disease progression before the infection requires hospitalizations or other intensive interventions.
Additional observational studies to evaluate the efficacy of Avigan as part of early treatment in COVID-19 patients are also initiated.
Avigan® is a trademark of FUJIFILM Toyama Chemical Co., Ltd.
https://www.drreddys.com/media/928938/2021-01-avigan-trial-update_v1.pdf